Acute graft-versus-host disease
Conditions
Interventions
Observation group:None
Sponsors
Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Inclusion criteria a) Diagnosed with hematological diseases, such as acute leukemia, chronic leukemia, lymphoma, multiple myeloma, severe aplastic anemia, etc., and planned to receive allo-HSCT treatment, the HLA types of the donor and recipient are fully or half-matched. b) The patient's age is >= 18 years old, with no gender restrictions; c) According to the Eastern Cooperative Oncology Group Physical Condition Score (ECOG PS) of the United States, it is 0 to 2 points; d) Having sufficient organ function is defined as follows: a. Liver function: Serum total bilirubin (TBIL) 30g/L. b. Renal function: Serum creatinine (Cr) = 50 ml/min (calculated using the CKD-EPI formula). c. Coagulation function: The International normalized ratio (INR) is <= 1.5, and the prothrombin time (PT) or activated partial thromboplastin time (APTT) is <= 1.5×ULN. e) The patient or his/her legal representative signs the informed consent form and is willing to cooperate throughout the entire research process.
Exclusion criteria
Exclusion criteria: 2. Exclusion criteria f) ECOG score > 2; g) Suffering from mental disorders or other conditions and unable to cooperate with the requirements of research, treatment and monitoring; h) Combined with severe functional disorders of important organs such as the heart, liver, and kidneys, such as New York Heart Association (NYHA) cardiac function classification grade III - IV Child-Pugh liver function classification grade B or above, and estimated glomerular filtration rate (eGFR) < 30 mL/min/1.73m^2; i) HIV and active hepatitis are known and the serological response is positive. j) There were active infections before transplantation, such as bacterial, viral, fungal infections, etc., and they were not effectively controlled. k) Having received immunomodulatory therapy within 3 months before enrollment, such as high-dose glucocorticoids, immunosuppressants, cytokine therapy, etc., may affect the cytokine test results.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall survival rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Progression Free Survival, PFS;Event Free Survival, EFS; | — |
Countries
China
Contacts
Public ContactDonghua Zhang
Tongji Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology
Outcome results
None listed